Supravalvular aortic stenosis (SVAS) is an inherited vascular disease that can cause heart failure and death. SVAS can be inherited as an autosomal dominant trait or as part ofa developmental disorder, Williams syndrome (WS). In recent studies we presented evidence suggesting that a translocation disrupting the elastin gene caused SVAS in one family while deletions involving the entire elastin locus caused WS. In this study, pulsed-field, PCR, and Southern analyses showed that a 100-kb deletion of the 3' end of the elastin gene cosegregated with the disease in another SVAS family. DNA sequence analysis localized the breakpoint between elastin exons 27 and 28, the same region disrupted by the SVAS-associated translocation. These data indicate that mutations in the elastin gene cause SVAS and suggest that elastin exons 28-36 may encode critical domains for vascular development. (J. Clin. Invest. 1994.
Introduction
Supravalvular aortic stenosis (SVAS) 1 is an inherited vascular disorder ( 1 ) . Narrowing of the ascending aorta is a prominent feature of this disease, but other arteries, including the pulmonary arteries, are often affected. If untreated, SVAS may cause myocardial hypertrophy, heart failure, and death. The incidence of SVAS is estimated to be 1 in 25,000 live births (Birth Defects and Genetic Diseases Branch Personnel, Metropolitan Atlanta Congenital Defects Program, Centers for Disease Control, Atlanta, GA, personal communication). The vascular abnormalities typical of SVAS can appear as an isolated case, an autosomal dominant trait, or as part of a second disease, Williams syndrome (WS) (1) (2) (3) . In addition to vascular disease, WS manifestations include mental retardation, gregarious disposition, premature aging ofskin and graying ofhair, lax joints early in life followed byjoint contractures later in life, diverticulosis of the bladder and colon, hernias, hoarse voice, and dysmorphic facial features (2) (3) (4) .
In previous experiments we demonstrated linkage between SVAS and the elastin gene in two families (5) ; recombination between these loci was not observed, making elastin a candidate gene for SVAS. We then showed that a balanced translocation associated with SVAS in one family disrupted the 3' end of the elastin gene (6, 7) . In WS, by contrast, we discovered submicroscopic deletions involving one entire elastin allele (8) . These data lead to the hypothesis that mutations involving part of the elastin gene cause familial SVAS while large deletions involving an entire elastin allele and adjacent loci cause WS. In this study, we describe a second SVAS-associated mutation (a 100-kb deletion) that disrupts the elastin gene, supporting the involvement of elastin in this disorder. This deletion, and the previously described translocation, both disrupt the 3' end of the gene, suggesting that these domains may be important for elastogenesis.
Methods
Phenotypic evaluation. Informed consent was obtained from all study participants in accordance with standards established by local institutional review boards. To determine if family members and spouses had signs of SVAS or WS, physical examinations and echocardiograms were performed by a medical geneticist as described (5, 9) . DNA analysis. Approximately 40 ml of blood was obtained from each family member for genetic analyses. Human genomic DNA was purified from leukocytes and from Epstein-Barr virus-transformed cell lines ( 10, 11 ). 5 mg of DNA from each individual was digested with restriction endonucleases (Molecular Biology Resources, Inc., Milwaukee, WI, and New England Biolabs Inc., Beverly, MA) overnight under conditions recommended by the manufacturer supplemented with 4 mM spermidine. DNA fragments were separated by agarose gel electrophoresis, denatured in 0.4 N NaOH for 20 min, and transferred overnight (12) transmission of SVAS is apparent. The proband (II-2) had right ventricular hypertrophy, supravalvular pulmonic stenosis (SVPS), bilateral narrowing of the pulmonary arteries (left more severe than right), and a diffusely narrowed ascending aorta with a discrete supravalvular narrowing diagnosed by cardiac catheterization at 6 wk of age. This patient also had intermittent acrocyanosis and hypertension. The most recent echocardiogram at 16 mo ofage showed mild SVAS, moderate right ventricular hypertrophy, narrowed pulmonary arteries, and improvement of SVPS. Peak pulmonary artery velocity measured 3 m/s (normal, 0.7-1.1 m/s) and peak aortic velocity was 3 m/s (normal, 1.2-1.8 m/s) with aortic turbulence noted on Doppler studies. The proband also had some features common to WS, including dolichocephaly, bitemporal narrowness, outer canthal distance < 2 SD below the mean, periorbital fullness, broad mouth, full cheeks, a hoarse voice, and hypersensitivity to loud noises. The diagnosis of WS was not made in this child because the patient did not show other features of the disorder; she had normal serum calcium levels, a normal urine calcium/creatinine ratio, normal psychomotor development, and normal growth parameters (length, weight, and head circumference all between the 25th and 50th percentile). High resolution chromosome studies and renal ultrasound were normal. This child was treated with phenobarbital for seizures. The mother (I-1 ) of the proband had a history of seizures in adolescence. Since childhood she has had a grade III/VI early systolic murmur heard best at the suprasternal notch and radiating to the left carotid. Doppler echocardiography studies were not completed in this individual. Other family members were unavailable for this study, but medical records indicated that at least two other family members were affected by SVAS. The mother's brother had narrowing of the entire pulmonary arterial tree diagnosed by cardiac catheterization and was treated for seizures. A maternal first cousin had severe bilateral peripheral pulmonic stenosis, right ventricular hypertrophy, and mild SVAS diagnosed by echocardiogram.
Identification of PFGE and Southern anomalies in DNA from SVAS patients. To test the hypothesis that mutations in the elastin gene cause SVAS, we used elastin genomic probes ( Fig. 2) to screen for anomalous restriction fragments in DNA from members of SVAS K2049. Using Southern analyses, elastin genomic probe pELN5-2 identified anomalous EcoRV restriction fragments of 8.5 kb in affected family members but not in unaffected members (Fig. 1) To confirm these findings and resolve the mechanism of this anomaly, we repeated these experiments using pulsed-field gel electrophoresis (PFGE). High molecular weight DNA extracted from lymphoblastoid cells of affected and unaffected family members was incubated with the restriction enzyme NotI. The resultant restriction fragments were separated by PFGE and transferred to nylon membranes. Hybridization with elastin genomic clones pELN5-2 and pELN5-3 revealed Notl fragments of 600 and 700 kb in affected members of K2049 (Fig. 3 A) . By contrast, in unaffected members of this family, only the 700-kb NotI fragment was observed. These anomalous restriction fragments were not identified in DNA from controls, so they are unlikely to be neutral polymorphisms or the result ofvariable methylation. These data suggest that an SVAS-associated mutation is located near the elastin locus. Possible mutations that could explain these data include a rare NotI site polymorphism cosegregating with the disease, a deletion, an insertion that creates a NotI site, an inversion, or a translocation.
The SVAS-associated mutation disrupts the elastin gene. To define the location and character of the SVAS-associated mutation, we used genomic subclones that span the 3' half of the elastin gene (Fig. 2) to probe NotI filters of DNA from affected and unaffected family members. In affected members ofthis family, the more 5' elastin probes (pELN5-2, pELN5-3) detected the 600-kb anomalous NotI fragment (Fig. 3 A) and the 700-kb fragment that was also detected in unaffected family members and control subjects. By contrast, the 3' elastin probe pELN5-4 identified only the 700-kb NotI fragment in both affected and unaffected family members (Fig. 3 A, and data not shown). These data suggest that the SVAS-associated mutation is a deletion affecting sequences in the 3' region of the elastin gene with a breakpoint within sequences covered by pELN5-3. A translocation is unlikely because pELN5-4 would be expected to identify a different anomalous fragment. These data are not consistent with a novel NotI polymorphism, an insertion, or an inversion because pELN5-4 would also detect the 600-kb anomalous NotI fragment.
To confirm these findings and further define the mutation, we repeated these experiments using Southern analyses. An 8.5-kb EcoRV anomalous fragment detected with elastin probes pELN5-2 and pELN5-3 was not seen with elastin probes pELN5-4 (Fig. 3 B) . These data are consistent with a deletion with a breakpoint in sequences represented by pELN5-3. Additional data substantiated this hypothesis. Elastin probe pELN5-3 detected anomalous restriction fragments in DNA samples from affected individuals with BclI, HindIII, Sacd, and PvuII (data not shown). pELN5-2 detected identical anomalous Bcl I, Sacd, and PvuII restriction fragments, but no anomalous fragments were detected in HindIII digests with pELN5-2 (these probes were generated from HindIII digests of a large elastin clone as shown in Fig. 2) . Of the elastin probes tested, only pELN5-3 detected an anomalous fragment in HindIII digests of affected family members (data not shown); pELN5-2 and pELN5-4 all identified HindIII fragments of the predicted size in affected and unaffected members of this kindred. No anomalous restriction fragments were defined with any enzyme tested by the 3' elastin probe pELN5-4. These data strongly suggest that the SVAS-associated mutation is a deletion beginning with sequences represented by elastin probe pELN5-3 and extending in a 3' direction.
To confirm these findings and refine the location of the mutation, we cloned the elastin gene from an affected member of K2049. A cosmid library was generated from partially cut, size-selected DNA obtained from affected individual -E. Fig. 4 , the sequences of N-3 and D-2.9 are identical for -231 bases and then diverge. The point of divergence presumably represents the deletion breakpoint and lies in intronic sequence -366 bases proximal ofexon 28. The DNA sequences 3' ofthe breakpoint (Fig. 4) showed no homology to any known genes when entered into GenBank.
To confirm that the 14 D clones represent the deletion allele and did not result from cloning artifacts, a 4.5-kb HindIll fragment representing D sequence 3' of the breakpoint was used to probe pulsed-field filters. This probe detected the 700-kb normal NotI fragment and the 600-kb aberrant fragment in genomic DNA of a member of K2049 who carried the SVASassociated mutation (Fig. 5) . By contrast, DNA from unaffected family members and controls gave only the expected 700-kb band. If D clones resulted from cloning artifacts, this probe would detect novel abberrant fragments in DNA samples from both affected and unaffected individuals. Since probes from either side of the breakpoint detect identical NotI fragments, the SVAS-associated deletion must be relatively small (-100 kb). Southern blots of DNA from K2049 were also probed with D and other breakpoint clones. The expected N TTTGACAGAGTCTTGCTCTGTCGCCCAGGCTGGAATGCAGTGGTACGATCTGGCTCCCTGCAGCCTCCATCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTTCC 
D -----------------------------------------------------------------------------------------------------------N AAGTAGCTGGGATTACAGGCGCCCGCCACCACGCCTGGCTAATTTTTGTATTTTTCGTAGAAACAGGGTTTCACCGTGTTGGCCAGGCTGGTCTCAAACTCCTGACC D ---------------------------------------------------------------------------__--____________________________-
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These data show that D represents the deletion allele and that the deletion Not I spans 100 kb.
anomalous fragments were seen with BclI-, EcoRV-, PvuII-, and SacI-digested DNA from affected individuals when probed with clones 3' of the breakpoint; no anomalous fragments were observed when these clones were used to analyze DNA from unaffected family members and controls (data not shown). To further confirm that the 14 D clones represent deletion alleles and are not cloning artifacts, oligonucleotide primer pairs (403fwd and 403rev) were generated on either side ofthe deletion for PCR analysis of the breakpoint (Fig. 6 A) . These primers produced a product of the predicted size (403 bp PCRs performed on template DNA from affected members of K2049 and a D clone (cD141-5; Fig. 6 B) . By contrast, these same primers failed to generate a product on unaffected family members. These data indicate that sequences derived from D clones represent the deletion allele and demonstrate that this 100-kb deletion disrupts the 3' end of elastin allele.
Discussion
Our data show that a 100-kb deletion associated with SVAS in one family disrupts the 3' end of the elastin gene. In previous studies we demonstrated complete linkage between SVAS and DNA markers at the elastin locus in two families (5) . We then showed that a balanced translocation that cosegregated with the disease in a third family disrupted the elastin gene (6, 7) . Linkage between SVAS and markers on chromosome 7q was recently observed in a fourth family (22) . This study demonstrates a second SVAS-associated elastin mutation, strongly suggesting that mutations in the elastin gene cause this disorder. Several additional lines of evidence support a role for elastin in SVAS. First, we recently demonstrated familial and de novo deletions ofthe entire elastin locus in patients with WS, a developmental disorder that includes SVAS (8) . Second, the physiology of the vascular system, particularly the aorta, suggests that abnormalities in elastin could cause SVAS. Hemodynamic strain on the vascular system is ameliorated by elastic fibers in the media; these fibers absorb energy during cardiac systole and release energy during diastole (23) . Reduced vascular elasticity would have a deleterious effect on vascular homeostasis, and since hemodynamic stress is greatest in the ascending aorta, this structure would be most severely affected. Third, the pathology of SVAS is consistent with a primary defect of elastin. In SVAS, elastic tissue is disrupted, disorganized, and reduced in content (24) . Increased collagen and smooth muscle cell hypertrophy, also observed in SVAS, presumably represent secondary phenomena. Finally, reports oftransient SVAS in patients with the Marfan syndrome support a role for elastic fibers in this disorder. Fibrillin, the protein implicated in Marfan syndrome, is a major component ofelastic fibers and interacts with elastin during fiber development (25) .
The precise mechanism of SVAS is not known, but it is interesting to note that both SVAS-associated mutations described thus far disrupt the 3' end of the elastin gene. The elastin gene consists of alternating hydrophobic and cross-linking domains. The hydrophobic domains are thought to represent a coiled coil and confer the protein's resiliency while the crosslinking residues are critical for intra-and intermolecular interactions. We do not yet know if the mutant elastin gene described here is expressed, but ifit is, a truncated protein lacking desmosine cross-link sites and two highly conserved cysteine residues would result (Fig. 7) . This protein would also lack a microfibril-associated glycoprotein (MAGP) binding site, which exists in the carboxy terminus of elastin (R. Mecham, personal communication). An (2) (3) (4) . Although the size of these WS-associated deletions is not yet known, they span at least 250 kb (our unpublished observations) and presumably disrupt adjacent, as yet undefined, genes. By contrast, the deletion described here is smaller ( 100 kb) and disrupts only the 3' end of the elastin gene. This mutation, and the previously described translocation involving the same elastin domains, is primarily associated with SVAS. Although isolated members of SVAS kindreds (for example, individual II-2 in the family described here) have additional connective tissue abnormalities (mild dysmorphic facial features, hoarse voice), none of the other features of WS (hypercalcemia, mental retardation, neurobehavioral features) have been observed in these patients. The elastin gene is expressed during development of the central nervous system (26), but the lack of cognitive and behavioral disorders in patients with autosomal dominant SVAS makes it unlikely that elastin mutations alone account for the WS phenotype. Instead, we hypothesize that hemizygosity at the elastin locus accounts for many of the connective tissue abnormalities seen in WS (including vascular disease), but that disruption of adjacent genes is the mechanism of additional WS features. Since no genotypic differences between members of autosomal dominant SVAS families have been identified, intrafamilial variation in the severity of vascular disease and the presence or absence of dysmorphic features probably results from other genetic and environmental factors. Further, careful phenotyping of SVAS and WS subjects, identification of genes adjacent to the elastin locus, and a detailed genotypic analysis of these patients may help elucidate the mechanisms underlying these disorders.
Although a number of DNA deletions have been sequenced, the precise mechanism of deletion is not known. In this study, sequence analysis ofthe breakpoint region identified a 300-bp Alu repeat within the elastin intron 27. Similar repetitive sequences were identified 3' of the breakpoint (Fig. 4) (30) . These agents, which reduce heart rate and blood pressure, may also prove effective in SVAS.
